Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds

After the UNGA High-Level Meeting on Tuberculosis—what next and how?

(2019) Suvanand Sahu et al.   Lancet Global Health

The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model

(2019) Yang Liu et al.   Nature Communications

Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents

(2019) Xianglong Hu et al.   ACS Medicinal Chemistry Letters

Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting M. ulcerans gene decay

(2019) Paul J. Converse et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels

(2018) Theresa O'Malley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB

(2018) Laura A. T. Cleghorn et al.   JOURNAL OF MEDICINAL CHEMISTRY

The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd

(2018) Ping Lu et al.   Scientific Reports

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer

(2018) Nicole Scherr et al.   Nature Communications

Pyrazolo[1,5-a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis

(2018) Xiaoyun Lu et al.   ACS Infectious Diseases

Exploiting the synthetic lethality between terminal respiratory oxidases to killMycobacterium tuberculosisand clear host infection

(2017) Nitin P. Kalia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB

(2017) N. Susantha Chandrasekera et al.   ACS Infectious Diseases

Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium InfectionIn Vivo

(2016) Garrett C. Moraski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis

(2016) Xiaoyun Lu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves

(2016) Kathleen Sprouffske et al.   BMC BIOINFORMATICS

Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB

(2016) Garrett C. Moraski et al.   ACS Infectious Diseases

Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents

(2015) Jian Tang et al.   ACS Medicinal Chemistry Letters

Lansoprazole is an antituberculous prodrug targeting cytochrome bc1

(2015) Jan Rybniker et al.   Nature Communications

Tuberculosis Treatment and Drug Regimens

(2015) G. Sotgiu et al.   Cold Spring Harbor Perspectives in Medicine

Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and “Anagrams” Generated Potent Antituberculosis Agents

(2015) Garrett C. Moraski et al.   ACS Infectious Diseases

Respiratory Flexibility in Response to Inhibition of CytochromecOxidase in Mycobacterium tuberculosis

(2014) Kriti Arora et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates

(2014) Garrett C. Moraski et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

(2014) Sunhee Kang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bactericidal Activity of an Imidazo[1, 2-a]pyridine Using a Mouse M. tuberculosis Infection Model

(2014) Yong Cheng et al.   PLoS One

Thiolates Chemically Induce Redox Activation of BTZ043 and Related Potent Nitroaromatic Anti-Tuberculosis Agents

(2013) Rohit Tiwari et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

(2013) Kevin Pethe et al.   NATURE MEDICINE

Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB

(2013) Katherine A. Abrahams et al.   PLoS One

A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis

(2013) Juliane Ollinger et al.   PLoS One

Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and nM Activity vs. Mycobacterium tuberculosis

(2013) Garrett C. Moraski et al.   ACS Medicinal Chemistry Letters

Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity

(2011) Garrett C. Moraski et al.   ACS Medicinal Chemistry Letters

Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation

(2010) R. S. Foti et al.   DRUG METABOLISM AND DISPOSITION

High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling

(2010) Priscille Brodin et al.   PLoS Pathogens

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

(2008) S. P. S. Rao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA